InsiderClue
Stocks · Health care · Pharmaceutical Preparations

XTL BIOPHARMACEUTICALS LTD

XTLB Clue Score30
United States CIK 0001023549
$1.98 -0.50% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.98 −51.59% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−2.6Net income−2.5Fiscal year 2017Operating income−1.2Net income−0.8Fiscal year 2018Operating income−0.8Net income3.6Fiscal year 2019Operating income−0.8Net income−0.8 −121.0%EPS, diluted−0.00Fiscal year 2020Operating income−0.9Net income−3.0EPS, diluted−0.01Fiscal year 2021Operating income−1.0Net income0.4EPS, diluted0.00Fiscal year 2022Operating income−0.9Net income−1.3 −409.9%EPS, diluted−0.00Fiscal year 2023Operating income−0.8Net income−1.8EPS, diluted−0.00Fiscal year 2024Revenue0.5Operating income−2.2Net income−1.0EPS, diluted−0.00
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Revenue n/a n/a n/a n/a n/a n/a n/a n/a 0.5
Growth
Operating income −2.6 −1.2 −0.8 −0.8 −0.9 −1.0 −0.9 −0.8 −2.2
Net income −2.5 −0.8 3.6 −0.8 −3.0 0.4 −1.3 −1.8 −1.0
Growth −121.0% −409.9%
EPS, diluted n/a n/a n/a −0.00 −0.01 0.00 −0.00 −0.00 −0.00
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Gross margin0.7%Operating margin−481.6%Net margin−227.7%Free cash flow margin−370.7%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Gross margin n/a n/a n/a n/a n/a n/a n/a n/a 0.7%
Operating margin n/a n/a n/a n/a n/a n/a n/a n/a −481.6%
Net margin n/a n/a n/a n/a n/a n/a n/a n/a −227.7%
Free cash flow margin n/a n/a n/a n/a n/a n/a n/a n/a −370.7%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−1.7Capital expenditure−0.0Free cash flow−1.7Fiscal year 2017Operating cash flow−1.1Fiscal year 2018Operating cash flow−0.8Fiscal year 2019Operating cash flow−0.9Capital expenditure−0.0Free cash flow−0.9Fiscal year 2020Operating cash flow−0.9Capital expenditure−0.0Free cash flow−0.9Fiscal year 2021Operating cash flow−1.0Fiscal year 2022Operating cash flow−0.9Fiscal year 2023Operating cash flow−0.7Fiscal year 2024Operating cash flow−1.6Capital expenditure−0.1Free cash flow−1.7
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Operating cash flow −1.7 −1.1 −0.8 −0.9 −0.9 −1.0 −0.9 −0.7 −1.6
Capital expenditure −0.0 n/a n/a −0.0 −0.0 n/a n/a n/a −0.1
Free cash flow −1.7 n/a n/a −0.9 −0.9 n/a n/a n/a −1.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash2.0Shareholders’ equity2.7Fiscal year 2017Cash3.3Shareholders’ equity3.6Fiscal year 2018Cash3.3Shareholders’ equity7.3Fiscal year 2019Cash4.5Shareholders’ equity6.5Fiscal year 2020Cash3.6Shareholders’ equity3.6Fiscal year 2021Cash3.0Shareholders’ equity5.3Fiscal year 2022Cash2.1Shareholders’ equity4.0Fiscal year 2023Cash1.4Shareholders’ equity2.2Fiscal year 2024Cash0.4Shareholders’ equity5.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024
Cash 2.0 3.3 3.3 4.5 3.6 3.0 2.1 1.4 0.4
Shareholders’ equity 2.7 3.6 7.3 6.5 3.6 5.3 4.0 2.2 5.4

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2024 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024
Revenue and profit
n/a n/a n/a n/a n/a n/a n/a n/a 0.5
Growth
n/a n/a n/a n/a n/a n/a n/a n/a 0.4
n/a n/a n/a n/a n/a n/a n/a n/a 0.0
Growth
0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1
1.3 1.2 0.8 0.8 0.9 1.0 0.9 0.7 1.6
−2.6 −1.2 −0.8 −0.8 −0.9 −1.0 −0.9 −0.8 −2.2
Growth
n/a n/a n/a n/a n/a n/a −1.3 −1.8 −1.2
n/a n/a n/a n/a n/a n/a n/a n/a −0.1
−2.5 −0.8 3.6 −0.8 −3.0 0.4 −1.3 −1.8 −1.0
Growth −121.0% −409.9%
Per share
n/a n/a n/a −0.00 −0.01 0.00 −0.00 −0.00 −0.00
n/a n/a n/a −0.00 −0.01 0.00 −0.00 −0.00 −0.00
Growth
274.0 470.2 514.2 514.2 514.2 532.0 544.9 544.9 673.0
n/a n/a n/a 514.2 514.2 615.5 544.9 544.9 704.2
Growth +0.0% +19.7% −11.5% −0.0% +29.2%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 36.9% in five years, which is dilution.
  • A net loss in 7 of 9 years on file.